Jong-Hwa Ahn

Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians? Focused on ACS or PCI-treated Patients.

With over 1.5 billion people, East Asians are the most populous race in the world. Health status in this population is an important global issue. In the contemporary trials of antithrombotic treatment, East Asian patients have a lower risk for atherothrombotic diseases (especially, Coronary Artery Disease [CAD]) and a higher risk for bleeding (especially, gastrointestinal bleeding and hemorrhagic stroke). Despite these observations, antithrombotic treatment strategies in East Asian patients are mainly based on the American or European guidelines that are derived from randomized, controlled trials including mostly Caucasians. Despite a low response to clopidogrel, East Asian patients with CAD show a similar or even a lower rate of ischemic event occurrence and higher bleeding risk compared with Caucasian patients. The latter is referred to as the East Asian Paradox, suggesting a dissimilar therapeutic window for antiplatelet therapy than Caucasians. In addition, different net clinical benefits have been observed between the races with potent P2Y12 inhibitors that may be related to racial differences in pharmacokinetic and pharmacodynamic profiles. Furthermore, there is emerging concern regarding differences between East Asian vs. Western patients in pharmacodynamic and clinical efficacies of anticoagulant agents. We now summarize experimental and clinical evidence of the efficacy and safety of antithrombotic agents in the East Asian population. We suggest the concept of race-tailored antithrombotic treatment in CAD patients and/or in patients undergoing percutaneous coronary intervention.

Antiplatelet Therapy Combinations and Thrombogenicity in Patients with Non-Valvular Atrial Fibrillation

Background and Objectives Combination antiplatelet therapy reduces the risk of ischemic stroke compared with aspirin monotherapy in non-valvular atrial fibrillation (NVAF) patients. The underlying mechanism, however, remains unclear. In addition, the association between platelet inhibition and thrombogenicity in NVAF has not been evaluated. Subjects and Methods We randomized 60 patients with NVAF that were taking 100 mg of aspirin daily (>1 month) to adding 75 mg of clopidogrel daily (CLPD group), 100 mg of cilostazol twice daily (CILO group), or 1000 mg of omega-3 polyunsaturated fatty acid twice daily (PUFA group). Biomarkers (von Willebrand factor antigen [vWF:Ag], fibrinogen, D-dimer, and high-sensitivity C-reactive protein [hs-CRP]) and platelet reactivity (PR), which were the levels stimulated by adenosine diphosphate (ADP), thrombin-receptor agonist peptide, collagen, and arachidonic acid, were measured at baseline and 30-day follow-up. Results Combination antiplatelet therapy significantly reduced vWF:Ag and fibrinogen levels (7.7 IU/dL, p=0.015 and 15.7 mg/dL, p=0.005, respectively), but no changes were found in D-dimer and hs-CRP levels. The CLPD and CILO groups showed fibrinogen and vWF:Ag level reductions (24.9 mg/dL, p=0.015 and 9.3 IU/dL, p=0.044, respectively), whereas the PUFA group did not show any differences in biomarkers. Irrespective of regimen, the changes in fibrinogen and vWF:Ag levels were mainly associated with the change in ADP-mediated PR (r=0.339, p=0.008 and r=0.322, p=0.012, respectively). Conclusion In patients with NVAF, combination antiplatelet therapy showed reductions for vWF:Ag and fibrinogen levels, which may be associated with the inhibitory levels of ADP-mediated PR. The clinical implications of these findings need to be evaluated in future trials.

TICAGRELOR VERSUS CLOPIDOGREL IS ASSOCIATED WITH BETTER RECOVERY OF LV FUNCTION AFTER ACUTE MYOCARDIAL INFARCTION

Background: Recovery of LV function following AMI is associated with the risk of long-term CV mortality and CHF progression. We sought to evaluate the predictors of recovery of LV function in AMI patients.nnMethods: AMI patients treated with uneventful PCI were prospectively enrolled (n=224). At 30-

CLINICAL EFFICACY OF HIGH-FLOW OXYGEN THERAPY THROUGH NASAL CANNULA IN PATIENTS WITH ACUTE HEART FAILURE

Background: Acute heart failure (AHF) is commonly complicated with pulmonary edema following hypoxemia. High-flow oxygen therapy through nasal cannula (HFNC) is may offer an alternative to invasive ventilation in those patients with uncorrectable hypoxemia by conventional oxygen therapy. However,

COMPARISON BETWEEN A NEW GRADING SCALE INCLUDING PLATELET FUNCTION TEST AND THE CURRENT BLEEDING SCALES IN PATIENTS WITH ACUTE CORONARY SYNDROME USING PRASUGREL

background: Bleeding is recognized as a major risk factor for mortality after coronary intervention. New antiplatelet agents reduced the ischemic events with a tradeoff of bleeding risks. However, the current bleeding scales were largely made by the patient factors, and therefore, they might be unreliable in cases using potent antiplatelet agents. In these patients, the degree of platelet inhibition might be considered as a risk factor of bleeding events.

Paraparesis after Primary Percutaneous Coronary Intervention for ST-segment Elevation Myocardial Infarction: Combined Uncommon Complications of Acute Aortic Syndrome in a Patient

Acute aortic syndrome complicated by both ST-segment elevation myocardial infarction (STEMI) and spinal ischemia is exceedingly rare. We herein report the case of a 66-year-old man who presented with paraparesis after primary percutaneous coronary intervention for STEMI. He was found to have an intramural hematoma of the ascending aorta and a severe dissection in the descending aorta, which led to both STEMI and paraparesis.

Coexistence of chronic myeloid leukemia and pulmonary plasmacytoma mimicking primary lung cancer

A 61-year-old man was diagnosed with the simultaneous occurrence of chronic myeloid leukemia (CML) and infiltrative intrathoracic plasmacytoma, radiologically mimicking bronchogenic carcinoma. Following the administration of imatinib mesylate (IM; 400xa0mg/day), both hematologic and partial cytogenetic remission of CML were achieved. However, the pulmonary plasmacytoma was persistently aggravated. High-dose dexamethasone was added to the IM therapy because the patient refused radiotherapy to control the aggravated pulmonary plasmacytoma. Finally, he died due to pneumonia and multi-organ failure during concurrent administration of IM and high-dose dexamethasone.